Literature DB >> 12485912

Regulation of promoter activity of the APP gene by cytokines and growth factors: implications in Alzheimer's disease.

Y-W Ge1, D K Lahiri.   

Abstract

One of the major pathological hallmarks of Alzheimer's disease (AD) is the presence of brain depositions of senile plaques that are primarily composed of potentially toxic amyloid beta-peptide (Abeta), which is generated from a family of Abeta-containing precursor proteins (APP; 695-770 amino acids). The role of inflammatory cytokines and growth factors has been implicated in the pathogenesis of AD. Our goal is to study the effects of these factors on the regulation of APP gene expression. Here we compared APP promoter activity in the presence of different growth factors and cytokines such as brain-derived neurotrophic factor (BDNF), interleukin (IL-1), nerve growth factor (NGF), neurotrofin-3 (NT-3), transforming growth factor (TGF-beta1), and tumor necrosis factor (TNF-alpha1). PC12 neuronal cells, which were treated separately with these agents, were transfected with the construct containing either 190 bp APP proximal promoter region (-46 to 144 bp with respect to the transcription start site [+1]), 94 bp APP 5'-untranslated region (UTR, +50 to 144) or other 5'-UTR-deleted regions. Each construct was cloned upstream of a reporter chloramphenicol acetyl transferase gene (CAT). The treatment of PC12 cells with NGF stimulated reporter activity in all constructs tested. The treatment of cells with BDNF, NT3, TGF-beta1, or TNF-alpha stimulated reporter activity in a promoter/UTR-specific manner. Transfection with the complete -46 to 144 region retained the maximum stimulatory activity for any treatment tested in PC12 cells. These results suggest that the regulatory elements of the APP gene respond to the stimulation of different growth factors, cytokines, and interleukins. This is consistent with the effects of the different growth factors, cytokines, and interleukins on APP message and protein levels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12485912     DOI: 10.1111/j.1749-6632.2002.tb04684.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  28 in total

1.  Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling.

Authors:  Walter J Lukiw
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

Review 2.  Neuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptors.

Authors:  Chang Liu; Guohong Cui; Meiping Zhu; Xiangping Kang; Haidong Guo
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

3.  Nicotine alters the proteome of two human pancreatic duct cell lines.

Authors:  Joao A Paulo
Journal:  JOP       Date:  2014-09-28

Review 4.  Oxidative stress and β-amyloid protein in Alzheimer's disease.

Authors:  Zhiyou Cai; Bin Zhao; Anna Ratka
Journal:  Neuromolecular Med       Date:  2011-09-08       Impact factor: 3.843

Review 5.  The Distinct Role of ADAM17 in APP Proteolysis and Microglial Activation Related to Alzheimer's Disease.

Authors:  Meng Qian; Xiaoqiang Shen; Huanhuan Wang
Journal:  Cell Mol Neurobiol       Date:  2015-06-29       Impact factor: 5.046

6.  Association between interleukin-6 gene promoter -572C/G polymorphism and the risk of sporadic Alzheimer's disease.

Authors:  Mei-xia He; Wan-li Yang; Ming-ming Zhang; Ya-jun Lian; Hai-ying Hua; Jin-sheng Zeng; Li-rong Zhang
Journal:  Neurol Sci       Date:  2009-12-03       Impact factor: 3.307

7.  Apoptosis and in vitro Alzheimer disease neuronal models.

Authors:  P Calissano; C Matrone; G Amadoro
Journal:  Commun Integr Biol       Date:  2009

8.  Differences in extracellular matrix production and basic fibroblast growth factor response in skin fibroblasts from sporadic and familial Alzheimer's disease.

Authors:  Catia Bellucci; Cinzia Lilli; Tiziano Baroni; Lucilla Parnetti; Sandro Sorbi; Carla Emiliani; Eleonora Lumare; Paolo Calabresi; Stefania Balloni; Maria Bodo
Journal:  Mol Med       Date:  2007 Sep-Oct       Impact factor: 6.354

9.  Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition.

Authors:  Paramita Chakrabarty; Karen Jansen-West; Amanda Beccard; Carolina Ceballos-Diaz; Yona Levites; Christophe Verbeeck; Abba C Zubair; Dennis Dickson; Todd E Golde; Pritam Das
Journal:  FASEB J       Date:  2009-10-13       Impact factor: 5.191

10.  Initial description of the human NLRP3 promoter.

Authors:  J P Anderson; J L Mueller; A Misaghi; S Anderson; M Sivagnanam; R D Kolodner; H M Hoffman
Journal:  Genes Immun       Date:  2008-08-21       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.